Osteosarcoma Market: Accelerating Growth and Pipeline Impact by 2034- DelveInsight

DelveInsight's "Osteosarcoma Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Osteosarcoma, historical and forecasted epidemiology as well as the Osteosarcoma market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Osteosarcoma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Osteosarcoma Market Forecast
https://www.delveinsight.com/sample-request/osteosarcoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Osteosarcoma Market Report:
• The Osteosarcoma market size is anticipated to grow with a significant CAGR during the study period (2020-2034).
• In february 2026, A biologics license application (BLA) for OST-HER2, targeting recurrent, fully resected pulmonary metastatic osteosarcoma, is currently being prepared for submission to the FDA. According to a press release from OS Therapies, the company has begun the BLA filing process to support the use of this therapy in preventing disease recurrence.
• In October 2025, OS Therapies is pursuing global approvals for its osteosarcoma vaccine following positive Phase IIb results. The company's candidate, OST-HER2, demonstrated a significant improvement in overall survival among patients with recurrent, fully resected pulmonary metastatic osteosarcoma. In the Phase IIb trial (NCT04974008), 75% of patients treated with the immunotherapy were alive after two years, compared to 40% in the historical control group, reflecting a statistically meaningful benefit.
• In June 2025, OS Therapies announced that it has received positive written feedback from the U.S. Food and Drug Administration (FDA) following a Type D meeting held in mid-June. This feedback supports the company's strategy to use an external control arm in its planned Biologics License Application (BLA) for its lead candidate, OST-HER2. The therapy, a Listeria monocytogenes-based immuno-oncology asset, was originally developed by Advaxis and fully acquired from Ayala Pharmaceuticals in April 2025. According to the company, the FDA's guidance helps clarify the regulatory pathway for OST-HER2 in preventing recurrence in pediatric osteosarcoma, an ultra-rare condition where conducting randomized, placebo-controlled trials is both ethically and practically challenging.
• In January 2025, OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company focused on immunotherapies and targeted drug conjugates for cancer, has announced positive results from its Phase 2b trial (NCT04974008) of OST-HER2 (OST31-164). This HER2-targeted immunotherapy is being developed for the prevention of recurrent, fully resected, lung metastatic osteosarcoma, a rare pediatric-designated indication. The study met its primary endpoint of 12-month event-free survival (EFS), showing a statistically significant improvement compared to historical controls. Additionally, interim 1-year and 2-year data indicate a strong trend favoring overall survival (OS) in OST-HER2-treated patients. Notably, all patients who met the 12-month EFS endpoint remain alive.
• The preferred second-line (relapsed/refractory or metastatic) therapies by the NCCN include ifosfamide (high dose) and etoposide, regorafenib, and everolimus.
• FUSILEV (levoleucovorin) and KHAPZORY (levoleucovorin) was FDA-approved as "rescue" therapy after high-dose methotrexate treatment in osteosarcoma. FUSILEV was FDA approved in March 2008 and KHAPZORY was launched in 2019 as a lifecycle management extension of FUSILEV, just before generics entered the market. After patent expiration, FUSILEV was discontinued, but clinicians continue to use either KHAPZORY or generic levoleucovorin, as all products have the same indication for methotrexate rescue in osteosarcoma.
• Among the 7MM, the United States has captured the highest market share of osteosarcoma in 2024.
• Among all the subtype specific cases, around 80% were of conventional osteosarcoma in 2024.
• Osteosarcoma is more common in males as compared to females.
• Osteosarcoma is more common in children, teens, and young adults between the ages of 10 and 30, and only 1 in 10 osteosarcomas occur in people older than 60.
• Key Osteosarcoma Companies: Takeda, Y-mAbs Therapeutics, OS Therapies, AlaMab Therapeutics, CSPC Pharmaceutical, Dana-Farber Cancer Institute, MedPacto, Inc., K-Group, Beta, Inc., H. Lee Moffitt Cancer Center, Hansoh BioMedical R&D Company, Ipsen, UNICANCER, Adaptimmune, M.D. Anderson Cancer Center, and others
• Key Osteosarcoma Therapies: MEPACT (mifamurtide), DANYELZA (naxitamab 15-096), OST-HER2 (OST31-154), ALMB-0168, Olaparib, Vactosertib, ZN-c3, Nivolumab, HS-20093, Cabozantinib, cisplatin, Afamitresgene autoleucel, Aldesleukine, and others
• The Osteosarcoma epidemiology based on gender analyzed that males contributes to higher incident cases as compared to females
• The Osteosarcoma market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Osteosarcoma pipeline products will significantly revolutionize the Osteosarcoma market dynamics.

Osteosarcoma Overview
Osteosarcoma is a rare and aggressive type of bone cancer that typically develops in the long bones, such as the arms or legs, near the growth plates. It primarily affects children, teenagers, and young adults, though it can occur at any age. Symptoms include bone pain, swelling, and reduced joint movement. The exact cause is often unknown, but genetic factors and prior radiation exposure may contribute. Treatment usually involves a combination of surgery to remove the tumor and chemotherapy to target cancer cells. Early diagnosis and advanced treatments have improved survival rates, especially for localized cases.

Get a Free sample for the Osteosarcoma Market Report
https://www.delveinsight.com/report-store/osteosarcoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Osteosarcoma Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Osteosarcoma Epidemiology Segmentation:
The Osteosarcoma market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Osteosarcoma
• Prevalent Cases of Osteosarcoma by severity
• Gender-specific Prevalence of Osteosarcoma
• Diagnosed Cases of Episodic and Chronic Osteosarcoma

Download the report to understand which factors are driving Osteosarcoma epidemiology trends @ Osteosarcoma Epidemiology Forecast
https://www.delveinsight.com/sample-request/osteosarcoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Osteosarcoma Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Osteosarcoma market or expected to get launched during the study period. The analysis covers Osteosarcoma market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Osteosarcoma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Osteosarcoma Therapies and Key Companies
• MEPACT (mifamurtide): Takeda
• DANYELZA (naxitamab 15-096): Y-mAbs Therapeutics
• OST-HER2 (OST31-154): OS Therapies
• ALMB-0168: AlaMab Therapeutics and CSPC Pharmaceutical
• Olaparib: Dana-Farber Cancer Institute
• Vactosertib: MedPacto, Inc.
• ZN-c3: K-Group, Beta, Inc.
• Nivolumab: H. Lee Moffitt Cancer Center
• HS-20093: Hansoh BioMedical R&D Company
• Cabozantinib: Ipsen
• cisplatin: UNICANCER
• Afamitresgene autoleucel: Adaptimmune
• Aldesleukin: M.D. Anderson Cancer Center

Discover more about therapies set to grab major Osteosarcoma market share @ Osteosarcoma Treatment Market
https://www.delveinsight.com/sample-request/osteosarcoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Osteosarcoma Market Drivers
• Increasing incidence of osteosarcoma, particularly among adolescents and young adults
• Rising focus on targeted therapies and immunotherapy for rare cancers
• Advancements in precision medicine and genomic profiling improving treatment strategies
• Growing investment in oncology R&D and orphan drug development
• Improved diagnostic techniques enabling early detection and intervention
• Supportive regulatory frameworks, including orphan drug designations and fast-track approvals
• Expanding pipeline of novel therapies, including kinase inhibitors and cell-based treatments

Osteosarcoma Market Barriers
• Limited patient population due to the rare nature of the disease
• High failure rates in clinical trials for new therapies
• Lack of significant breakthroughs compared to other cancer types
• High cost of advanced treatments such as targeted therapies and immunotherapies
• Severe side effects associated with chemotherapy and combination treatments
• Challenges in conducting large-scale clinical trials due to small patient pool
• Limited awareness and delayed diagnosis in certain regions

Scope of the Osteosarcoma Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Osteosarcoma Companies:Dana-Farber Takeda, Y-mAbs Therapeutics, OS Therapies, AlaMab Therapeutics, CSPC Pharmaceutical, Cancer Institute, MedPacto, Inc., K-Group, Beta, Inc., H. Lee Moffitt Cancer Center, Hansoh BioMedical R&D Company, Ipsen, UNICANCER, Adaptimmune, M.D. Anderson Cancer Center, and others
• Key Osteosarcoma Therapies: MEPACT (mifamurtide), DANYELZA (naxitamab 15-096), OST-HER2 (OST31-154), ALMB-0168, Olaparib, Vactosertib, ZN-c3, Nivolumab, HS-20093, Cabozantinib, cisplatin, Afamitresgene autoleucel, Aldesleukine, and others
• Osteosarcoma Therapeutic Assessment: Osteosarcoma current marketed and Osteosarcoma emerging therapies
• Osteosarcoma Market Dynamics: Osteosarcoma market drivers and Osteosarcoma market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Osteosarcoma Unmet Needs, KOL's views, Analyst's views, Osteosarcoma Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.